Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Bitcoin Holder MicroStrategy And 4 More Short Squeeze Stocks That Could Soar This Week

Published 24/10/2022, 15:40
Updated 24/10/2022, 16:40
© Reuters.  Bitcoin Holder MicroStrategy And 4 More Short Squeeze Stocks That Could Soar This Week

© Reuters. Bitcoin Holder MicroStrategy And 4 More Short Squeeze Stocks That Could Soar This Week

Potential short squeeze plays gained steam in 2021 and has continued through 2022 with new traders looking for the next huge move.

High short interest and a high cost to borrow are among the common traits that could lead to a short squeeze. Here’s a look at the top five short squeeze candidates based on the Fintel short squeeze leaderboard.

PaxMedica Inc: Clinical stage biopharmaceutical company PaxMedica Inc (NASDAQ: PXMD) is developing treatments for autism spectrum disorder. The company held its IPO in August 2022 with a pricing of $5.25 per share. Fintel data shows 24% of the float short and a cost to borrow of 104.8%. The stock moves up 11 places on the leaderboard for the week.

IBio: Healthcare company IBio (AMEX:IBIO) jumps 33 places on the leaderboard to rank second for the week. Data shows 120.1% of the float short and a cost to borrow of 5.6%. Shares are up over 200% year-to-date, likely leading to an increase in the number of people betting against the company.

Related Link: Betting Against Bitcoin And Michael Saylor, Could MicroStrategy See A Short Squeeze?

MicroStrategy Inc: Software company MicroStrategy Incorporated (NASDAQ: MSTR) rejoins the leaderboard, moving up 12 places. The company, which is also one of the biggest holders of Bitcoin (CRYPTO: BTC) has been a high short-interest stock with an increase in investors betting against the company and also against the leading cryptocurrency. Data shows 35.8% of the float short and a cost to borrow of 29.4% for MicroStrategy. The stock moved up 12 places to rank third for the week.

Greenwich LifeSciences: Clinical stage biopharmaceutical company Greenwich LifeSciences (NASDAQ: GLSI) ranks fourth for the week after topping the leaderboard last week. Data shows 27.9% of the float short, down slightly from last week’s 28.5%. The cost to borrow on shares is 11.3%, up from last week’s 11.1%. The stock has frequently been on the leaderboard in 2022.

Aerovate Therapeutics: Clinical stage biopharmaceutical company Aerovate Therapeutics (NASDAQ: AVTE) slides three places from last week to rank fifth for the week. Data shows 31.5% of the float short, in line with last week’s figure. The cost to borrow on shares is 6.9%, up slightly from last week’s 6.8%.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.